KGKonstantin Gospodinov

Konstantin Gospodinov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantin Gospodinov has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • RHYTHM AND CONDUCTION DISORDERS IN COVID-19: FROM MYOCARDIAL INJURY TO CLINICAL ARRHYTHMIAS

    by Zhivko Yovchev, Emil Popov, Konstantin Gospodinov

    COVID-19 is associated with a broad spectrum of rhythm and conduction disorders, particularly among hospitalized and critically ill patients. Arrhythmogenesis is multifactorial and reflects systemic inflammation, hypoxaemia, myocardial ischaemia or injury, myocarditis, autonomic imbalance, thromboembolic disease, electrolyte disturbances and drug-related proarrhythmia. Atrial fibrillation is the most frequently reported sustained arrhythmia, while ventricular tachyarrhythmias, bradyarrhythmias and atrioventricular conduction disturbances occur predominantly in patients with severe disease or myocardial injury. Contemporary population-based evidence also indicates that arrhythmic risk may persist beyond the acute infection, although the absolute risk and the contribution of direct viral myocardial injury remain incompletely defined. This review summarizes the principal mechanisms, clinical phenotypes and management considerations of COVID-19-related arrhythmias and highlights emerging evidence concerning post-acute autonomic dysfunction and long-term rhythm complications.

  • RISK FACTORS IN PATIENTS WITH COVID-19 DURING THE FIRST WAVE OF COVID-19

    by Emil Popov, Zhivko Iovchev, Klimentina Gospodinova, Konstantin Gospodinov

    The first registered case of COVID-19 in Bulgaria was reported on March 8, 2020. Following the initial manifestation of pulmonary disease and the declaration of an epidemic emergency situation, admissions of patients with cardiovascular diseases (CVD) were significantly reduced. During the period of the COVID-19 pandemic, an increased incidence of acute coronary syndrome (ACS) was observed among patients with newly diagnosed or recently recovered COVID-19 infection. Evidence emerged in the international literature regarding the influence of SARS-CoV-2 on ACE2 receptors and the induction of a systemic inflammatory process in the body. Considering the current concept of atherosclerosis and the role of inflammatory and anti-inflammatory factors, researchers focused their attention on the impact of COVID-19 on atherosclerotic plaque instability and the accelerated progression of ACS. In our follow-up study, the major risk factors for the development of ACS were investigated among patients hospitalized in the Department of Cardiology at University Hospital "Dr Georgi Stranski", Pleven, Bulgaria. Based on the analysis of the obtained results, a risk stratification model for patients with ACS and COVID-19 infection was developed.

  • Open Access

    Dapagliflozin use in routine management of heart failure with reduced ejection fraction: outcomes from the Bulgarian cohort of a large observational study (EVOLUTION-HF)

    by I. Gruev, K. Bletzova, I. Deenichina, G. Goranov, K. Gospodinov, G. Gyuzelev, M. Mihalev, S. Petranov, S. Yovev, V. Velchev

    Introduction: The EVOLUTION-HF is a prospective, multinational, real-world study designed to describe the demographic and clinical characteristics of patients initiating dapaglifl ozin for heart failure with reduced ejection fraction (HFrEF) in nine countries from the Central and Eastern Europe and Baltic Area. This manuscript presents the results of the Bulgarian cohort of the study. Methods: Enrolment period in Bulgaria was between February 2022 and October 2022, in 10 study sites. Demographic and clinical characteristics were collected at baseline (12 months before dapaglifl ozin initiation), and treatment for heart failure (HF), including guideline-directed treatment (GDMT) was collected prospectively until 12 months after dapaglifl ozin initiation. The HF treatment was administered as per routine clinical practice. Results: One hundred and fi fty patients were included in the full analysis set (mean age: 67 years, males 84%). At the time of initiation of dapaglifl ozin 10 mg/day, 69.3% of patients had treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors and 35.3% all four GDMTs in HF. Almost 98% of patients remained on dapaglifl ozin at 6 months and 12 months. Seven (10.12%) dapaglifl ozin discontinuations were recorded throughout the study. The discontinuation rate of dapaglifl ozin was 4.65 per 100 patient-years and the median time-to-discontinuation was not reached. One patient stopped dapaglifl ozin between baseline and 6 month and between 6 month and 12 month-data collection, respectively. GDMT patterns were relatively stable over one year. Conclusion: A high rate of persistence of dapaglifl ozin was observed at 12-month follow-up after initiation for HFrEF. A substantial gap was noted related to GDMT strategy optimization, with only one third of patients receiving all four GDMT pillars. These results obtained in real-world practice in Bulgaria point to the unmet need for targeted efforts to improve GDMT adoption in patients with HFrEF.


  • Open Access

    Myocarditis in treatment with immune checkpoint inhibitors (ICI)

    by K. Razlozhka, K. Gospodinov, V. Gitsov, S. Tisheva-Gospodinova

    Patients with cancer have multiple etiological factors for the development of myocarditis. Classical or conventional chemotherapy, radiotherapy and, more recently, immunotherapy have been described as possible etiological causes of myocarditis. In addition, patients with cancer are immunosuppressed and more susceptible to bacterial and viral infections that can cause myocarditis. This review discusses the many possible causes of myocarditis in patients with cancer. Special emphasis is placed on myocarditis induced by immune checkpoint inhibitors (ICI). ICI myocarditis usually affects male patients over 50 years of age who are being treated for lung cancer, melanoma or renal cell carcinoma and have multiple comorbidities. Clinical manifestations occur early, with elevated troponin and electrocardiogram changes. The mortality rate is high. Treatment consists of discontinuation of the causative ICI and corticosteroid therapy. Myocarditis caused by cyclophosphamide, anthracyclines, 5-fl uorouracil, cisplatin, carboplatin, proteasome inhibitors, immunomodulators, tyrosine kinase inhibitors, and radiotherapy was also reviewed.

  • Open Access

    Rhythm and conduction disorders as a manifestation of cardiotoxicity in cancer treatment

    by V. Gitsov, K. Gospodinov, S. Tisheva, K. Razlozhka

    Cardio-oncology is a new field, uniting two fields of medicine. With the improvement of anti-cancer therapies, the survival rate of patients is increasing, which is a prerequisite for the manifestation of cardiovascular diseases, including rhythm and conduction disorders. On the other hand, the drugs themselves used to treat cancer are associated with damage to the cardiovascular system. The purpose of this publication is to provide a brief overview of rhythm and conduction disorders resulting from treatment with anticancer drugs, to present the drugs with the highest risk of cardiotoxicity and the risk factors predisposing to it.

  • Open Access

    Severe cutaneous vasculitis as a symptom of right-sided infectious endocarditis in a patient with intravenous using of methadone: a clinical case

    by Y. M. Todorova, K. D. Gospodinov, M. E. Lukanov, S. T. Tisheva, Й. М. Тодорова, С. Т. Тишева Y. M. Todorova

    Бактериалната инфекция на ендокардната повърхност на сърцето причинява инфекциозен ендокардит (ИЕ). Най-често са засегнати сърдечните клапи или интракардиални устройства. В повечето случаи на десностранен инфекциозен ендокардит е засегната трикуспидалната клапа. Използването на наркотици като кокаин, хероин или други субстанции може да причини това заболяване. ИЕ може да се развие, ако метадонът не се прилага в съответствие с изискванията на метадоновата програма въпреки спирането на употребата на наркотици. При употребяващите наркотици Staphylococcus aureus е най-честата причина за десностранен инфекциозен ендокардит с белодробна септична емболия и персистираща бактериемия. Кожният васкулит, особено левкоцитокластичният васкулит, е рядка проява на ИЕ. A bacterial infection of the heart’s endocardial surface causes infectious endocarditis (IE). The heart valves or an intracardiac devices are most affected. In most cases of right-sided endocarditis, the tricuspid valve is involved. Using drugs like cocaine, heroin, or any number of others can cause this disorder. Infective endocarditis can develop if methadone is not administered in accordance with the Methadone program, despite the cessation of drug use. In drug users, Staphylococcus aureus is the most common cause of right-sided infective endocarditis with pulmonary embolism and persistent bacteraemia. Cutaneous vasculitis, particularly leukocytoclastic vasculitis, is a rare manifestation of IE.

  • DOES CHRONIC OBSTRUCTIVE PULMONARY DISEASE AFFECT THE CLINICAL COURSE OF HEART FAILURE?

    by Konstantin D. Gospodinov, Todorova Yoana M, Nadia Stancheva, Pavlina Glogovska, Snezhanka T. Tisheva, Georgi Stranski

  • Open Access

    Role of Single Nucleotide Polymorphism L55M in the Paraoxonase 1 Gene as a Risk and Prognostic Factor in Acute Coronary Syndrome

    by Krastina I. Doneva-Basheva, Konstantin Gospodinov, Tanya Tacheva, Dimo Dimov, Tatyana I. Vlaykova

    The aim of the current study is to explore the possible role of L55M, (rs 854560, 163T > A) SNP as a predisposing factor for acute coronary syndrome (ACS) and to assess its potency as a prognostic biomarker for short (1 year) survival and for median (5 years) and 9-year long patients’ outcome. Methods: The current work is a prospective case-control study with 77 patients with acute coronary syndrome (53 with ST-elevation myocardial infarction, STEMI, 14 with non-ST-elevation myocardial infarction, NSTEMI and 10 with unstable angina, UA) and 122 control individuals. Patients were followed-up for 9 years. The genotyping for PON1 L55M SNP was carried on by PCR-RFLP method. Results: The results of the genotyping for PON1 L55M SNP showed a statistically significant difference (p = 0.023) between the controls and the whole group of patients with acute coronary syndrome, as the individuals with genotype with at least one variant M allele had about 2.5-fold higher risk for developing ACS than those which are homozygous of the wild-type L allele (LL genotype). In patients with variant M allele genotypes (LM + MM) which suffer from non-ST-segment elevation ACS (NSTEACS, i.e., UA or NSTEMI), the serum levels of total cholesterol (TC) and triacylglycerols (TAG) are significantly higher than in NSTEACS patients with LL genotype (p = 0.022 for TC and p = 0.015 for TAG). There was no significant difference in the survival rate at the 1st, 5th and 9th year of follow-up between ACS patients with different genotypes, although it is worth to note that in the subgroup of NSTEACS, all patients (n = 13) with variant M allele genotypes (LM + MM) were alive at the end of the first year, while 2 of the patients with LL genotype (18.2%) were dead. Conclusions: The results of our current study suggest that the variant M allele and the M allele genotypes (LM + MM) of the PON1 L55M polymorphism are risk factors for acute coronary syndrome, especially for patients with STEMI, but do not support the possible effect of this polymorphism on the clinical progression and outcome of the patients with ACS either in short or long follow-up periods.


  • THE IMPACT OF AGE-RELATED SARCOPENIA ON SURVIVAL AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

    by Konstantin D. Gospodinov, Yoana M. Todorova, Snezhana T. Tisheva

    There is an increasing HF population resulting from the higher number of MI survivors and the widespread presence of diabetes, hypertension, CHD (Chronic Heart Filure), obesity and other chronic conditions. Cardiac dysfunction is the main factor that leads to reduced physical activity in patients with HF. The alternations in skeletal musculature often are present in the background of HF and can contribute to fatigue and dyspnea. Sarcopenia is a reduction in muscle mass and force, and it is right to say that it is one of the signs of “getting old”.The modern views on sarcopenia are that it is an outcome of many medical, behavioral and ecological factors, which are common in older people. Together with a sedentary lifestyle, it can be the main reason for disability in the late stages of human life. In our study, we examined the significance of reduced skeletal muscle tissue on mortality and survival of patients with diagnosed HF. The results showed that sarcopenia is a significant contributing factor for increased mortality [p = 0,022] and reduced survival rates [p = 0,033] in patients with HF II – IV class by NYHA. As a secondary goal we found there is significant correlation between age and sarcopenia [R²Linear = 0,057].